Evicenter
P&T meetings

BIM-IOL System

Open-angle glaucoma or ocular hypertension

Manufacturer
SpyGlass Pharma
Regulatory submission
NDA planned for 2028
Launch
Not announced
Last updated
129 sources

Product information and disease descriptionPlace of product in therapy

Approaches to treatment

150 evidence topics · 51 sources

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.